HomeComparePBBIF vs ORCC

PBBIF vs ORCC: Dividend Comparison 2026

PBBIF yields 0.50% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORCC wins by $1.0K in total portfolio value
10 years
PBBIF
PBBIF
● Live price
0.50%
Share price
$24.00
Annual div
$0.12
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.4K
Annual income
$51.65
Full PBBIF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — PBBIF vs ORCC

📍 ORCC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPBBIFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PBBIF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PBBIF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PBBIF
Annual income on $10K today (after 15% tax)
$42.50/yr
After 10yr DRIP, annual income (after tax)
$43.90/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, PBBIF beats the other by $43.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PBBIF + ORCC for your $10,000?

PBBIF: 50%ORCC: 50%
100% ORCC50/50100% PBBIF
Portfolio after 10yr
$20.9K
Annual income
$26.35/yr
Blended yield
0.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

PBBIF
No analyst data
Altman Z
1.8
Piotroski
6/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PBBIF buys
0
ORCC buys
0
No recent congressional trades found for PBBIF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPBBIFORCC
Forward yield0.50%9.79%
Annual dividend / share$0.12$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$20.4K$21.4K
Annual income after 10y$51.65$1.04
Total dividends collected$509.00$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: PBBIF vs ORCC ($10,000, DRIP)

YearPBBIF PortfolioPBBIF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$10,750$50.00$11,190$489.61$440.00ORCC
2$11,553$50.23$12,229$256.01$676.00ORCC
3$12,412$50.45$13,216$130.74$804.00ORCC
4$13,331$50.66$14,207$66.02$876.00ORCC
5$14,315$50.85$15,234$33.17$919.00ORCC
6$15,369$51.03$16,317$16.62$948.00ORCC
7$16,496$51.20$17,468$8.32$972.00ORCC
8$17,702$51.36$18,695$4.16$993.00ORCC
9$18,992$51.51$20,006$2.08$1.0KORCC
10$20,373$51.65$21,407$1.04$1.0KORCC

PBBIF vs ORCC: Complete Analysis 2026

PBBIFStock

Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.

Full PBBIF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this PBBIF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PBBIF vs SCHDPBBIF vs JEPIPBBIF vs OPBBIF vs KOPBBIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.